Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) FCF Margin (2016 - 2025)

ImmunityBio (IBRX) has disclosed FCF Margin for 12 consecutive years, with 185.98% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 101461.0% to 185.98% in Q4 2025 year-over-year; TTM through Dec 2025 was 272.53%, a 242753.0% increase, with the full-year FY2025 number at 272.53%, up 242753.0% from a year prior.
  • FCF Margin was 185.98% for Q4 2025 at ImmunityBio, up from 217.37% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 185.98% in Q4 2025 to a low of 730550.0% in Q1 2022.
  • A 5-year average of 106189.05% and a median of 37179.56% in 2021 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: surged 477939735bps in 2021, then crashed -68195144bps in 2022.
  • ImmunityBio's FCF Margin stood at 21036.41% in 2021, then crashed by -614bps to 150216.44% in 2022, then skyrocketed by 50bps to 75085.61% in 2023, then skyrocketed by 98bps to 1200.6% in 2024, then soared by 85bps to 185.98% in 2025.
  • Per Business Quant, the three most recent readings for IBRX's FCF Margin are 185.98% (Q4 2025), 217.37% (Q3 2025), and 305.93% (Q2 2025).